Arizona State Retirement System Buys 185 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Arizona State Retirement System lifted its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.6% in the 4th quarter, HoldingsChannel reports. The fund owned 31,224 shares of the biopharmaceutical company’s stock after purchasing an additional 185 shares during the quarter. Arizona State Retirement System’s holdings in Regeneron Pharmaceuticals were worth $22,242,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Rakuten Securities Inc. raised its position in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth $26,000. Private Wealth Management Group LLC increased its position in Regeneron Pharmaceuticals by 260.0% during the 4th quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after buying an additional 39 shares in the last quarter. Truvestments Capital LLC acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $39,000. Finally, Valley Wealth Managers Inc. acquired a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $49,000. 83.31% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on the company. Wells Fargo & Company reduced their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Wolfe Research assumed coverage on Regeneron Pharmaceuticals in a research report on Friday, November 15th. They set an “outperform” rating and a $1,150.00 target price on the stock. Bernstein Bank reduced their target price on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Citigroup reduced their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a “neutral” rating on the stock in a research report on Tuesday, January 28th. Finally, Sanford C. Bernstein reduced their target price on Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Stock Up 1.7 %

Shares of REGN opened at $687.15 on Thursday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $642.00 and a 52 week high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a market capitalization of $75.12 billion, a price-to-earnings ratio of 17.95, a PEG ratio of 2.34 and a beta of 0.08. The stock’s 50-day moving average price is $696.58 and its 200-day moving average price is $857.92.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $11.86 earnings per share. On average, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th will be given a dividend of $0.88 per share. The ex-dividend date of this dividend is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.51%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 2.30%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.